BioSpace - Print News Article

Octapharma AG’s Drive to Prevent and Eradicate FVIII Antibody Inhibitors in Haemophilia Treatment 9/13/2010 9:13:56 AM LACHEN, Switzerland--(BUSINESS WIRE)--In a showing of its continued commitment to eradicating today's major complication in the treatment of haemophilia with FVIII concentrates - i.e. anti-FVIII neutralising antibodies - Octapharma AG recently sponsored a symposium, "Inhibitors in Haemophilia A: Prevention, Current Management and Personalised Therapy Perspectives", on July 13, 2010 at the World Federation of Haemophilia's (WFH's) yearly congress. This year's location in Buenos Aires, Argentina, remarkably reflected Octapharma's steadfast interest in clinical benefit and cost effectiveness reaching the developing world. Octapharma's symposium brought together a consortium of international experts on blood coagulation disorders, each of them presenting on diverse topics relevant to the current and future management of patients with FVIII inhibitors, and on study results for the human, plasma-derived, von Willebrand factor (VWF)-containing FVIII concentrate, Octanate®.

Octapharma AG’s Drive to Prevent and Eradicate FVIII Antibody Inhibitors in Haemophilia Treatment
9/13/2010 9:13:56 AM

LACHEN, Switzerland--(BUSINESS WIRE)--In a showing of its continued commitment to eradicating today's major complication in the treatment of haemophilia with FVIII concentrates - i.e. anti-FVIII neutralising antibodies - Octapharma AG recently sponsored a symposium, "Inhibitors in Haemophilia A: Prevention, Current Management and Personalised Therapy Perspectives", on July 13, 2010 at the World Federation of Haemophilia's (WFH's) yearly congress. This year's location in Buenos Aires, Argentina, remarkably reflected Octapharma's steadfast interest in clinical benefit and cost effectiveness reaching the developing world. Octapharma's symposium brought together a consortium of international experts on blood coagulation disorders, each of them presenting on diverse topics relevant to the current and future management of patients with FVIII inhibitors, and on study results for the human, plasma-derived, von Willebrand factor (VWF)-containing FVIII concentrate, Octanate®.